TRxADE HEALTH, Inc. (MEDS)
NASDAQ: MEDS · IEX Real-Time Price · USD
5.84
0.00 (0.00%)
At close: May 17, 2024, 4:00 PM
5.70
-0.14 (-2.40%)
After-hours: May 17, 2024, 4:00 PM EDT
TRxADE HEALTH Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for TRxADE HEALTH stock has a target of 18.75, which predicts an increase of 221.06% from the current stock price of 5.84.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 1, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for TRxADE HEALTH is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| EF Hutton | EF Hutton | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +221.06% | Jun 1, 2023 |
| EF Hutton | EF Hutton | Strong Buy Maintains $26 → $19 | Strong Buy | Maintains | $26 → $19 | +221.06% | May 16, 2023 |
| Maxim Group | Maxim Group | Strong Buy Maintains $38 → $26 | Strong Buy | Maintains | $38 → $26 | +349.49% | Mar 28, 2023 |
| EF Hutton | EF Hutton | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 9, 2021 |
Financial Forecast
Revenue This Year
9.49M
from 8.27M
Increased by 14.67%
Revenue Next Year
n/a
from 9.49M
EPS This Year
-0.46
from -7.49
EPS Next Year
n/a
from -0.46
Revenue Forecast
| Revenue | 2024 |
|---|---|
| High | 9.8M |
| Avg | 9.5M |
| Low | 9.1M |
Revenue Growth
| Revenue Growth | 2024 |
|---|---|
| High | 18.0% |
| Avg | 14.7% |
| Low | 10.2% |
EPS Forecast
| EPS | 2024 |
|---|---|
| High | -0.47 |
| Avg | -0.46 |
| Low | -0.44 |
EPS Growth
| EPS Growth | 2024 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.